Paul Maruff, PhD

Professor Paul Maruff is one of the founders of Cogstate and served as Chief Science Officer before taking on the role of Chief Innovation Officer. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioural and cognitive dysfunction. Paul’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods to guide decision making in drug development and in clinical medicine.

He has worked extensively on method to identify subtle neurocognitive impairment, and to assess the efficacy of pharmacological treatment, in Alzheimer’s disease, mild cognitive impairment and the HIV dementia complex. He has extended this approach to identify cognitive dysfunction, and monitor treatment efficacy in psychiatric diseases such as schizophrenia, obsessive-compulsive disorder and depression in adults, attention deficit disorder, developmental dyspraxia and substance abuse in children.

Paul remains an active researcher. He is appointed Professor at the Florey Institute for Neuroscience and Mental Health. He is currently clinical co-chair of the Australian Imaging Biomakers and Lifestyle (AIBL) study. Paul has published over 450 research articles in international peer-reviewed scientific journals, and has co-authored 15 book chapters.

Chris Edgar, PhD

Dr. Chris Edgar is an experienced leader in cognitive assessment and clinical endpoint strategy who provides expert guidance to Cogstate’s pharmaceutical customers throughout all stages of trial conduct, from study design and test selection through final analysis.

Prior to joining Cogstate in 2018, Dr. Edgar oversaw clinical endpoint strategy for multiple neuroscience indications in the Patient-Centered Outcomes Research group at Roche. Dr. Edgar has held other key industry positions including Principle Scientist at Roche, Senior Clinical Lead at Bracket/UBC, and Scientific Director at Cognitive Drug Research Ltd. He holds a PhD in psychopharmacology from Northumbria University and has 20 years of pharmaceutical industry experience.

Kaycee Sink, MD, MAS

Dr. Kaycee Sink is the Chief Medical Officer at Cogstate where she leads the support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies. Dr. Sink is board certified in Internal Medicine and Geriatric Medicine with over 20 years of experience in clinical care and research in neurodegenerative disorders.

Prior to joining Cogstate, Dr. Sink worked at Genentech where she was Principal Medical Director in Neurodegeneration with leadership roles in the late-stage development of several molecules being studied for Alzheimer’s disease and other neurodegenerative disorders as well as digital applications for the same. She joined Genentech in 2017 after 13 years on faculty at Wake Forest School of Medicine, where she rose to tenured Full Professor of Medicine, Neurology, and Public Health Sciences. At Wake Forest School of Medicine, Kaycee served as interim Chief of Geriatrics, the Director of the Memory Assessment Clinic, and was the PI of the Clinical Core for the NIH funded Alzheimer’s Disease Center as well as an investigator/PI on multiple NIH and industry sponsored clinical trials in aging and Alzheimer’s disease.

Dr. Sink obtained her medical degree at the University of CA, San Francisco, and subsequently trained in internal medicine followed by clinical and research fellowships in geriatrics, also at UCSF. She continues to see patients and teach in the Memory Assessment Clinic as adjunct faculty at Wake Forest School of Medicine in Winston Salem, NC.

Karra Harrington, PhD

Dr. Karra Harrington is a Senior Clinical Scientist at Cogstate, where she supports biotech and healthcare customers with a focus on digital cognitive assessments. She plays a key role in the development and validation of Cogstate’s digital cognitive tests, ensuring they meet the highest scientific and clinical standards. Before joining Cogstate, Karra was an Assistant Research Professor at Penn State. Her research centered on developing smartphone-based cognitive assessments designed to measure cognition remotely and in real-world settings.

Karra holds a PhD in Neuroscience from the University of Melbourne and a Master of Clinical Psychology from Deakin University. She was board-endorsed as a Clinical Psychologist in Australia and previously practiced for four years before transitioning to research in the United States. With over 50 peer-reviewed publications and numerous conference presentations, Karra is a recognized expert in Alzheimer’s disease research and digital cognitive assessment methodologies.